Antitumor activity of erythromycin on human neuroblastoma cell line (SH-SY5Y)

  • Jia Yongsheng (贾勇圣)
  • Ma Xiaoyun (马晓芸)
  • Wei Xiaoli (魏晓莉)
  • Li Xin (李 昕)
  • Yan Haitao (闫海涛)
  • Liu Xiaoyan (刘晓燕)
  • Zheng Jianquan (郑建全)


Antitumor effects of erythromycin and the related mechanism were investigated in the present study. Neuroblastoma cells (SH-SY5Y) were exposed to erythromycin at different concentrations for different durations. Cell proliferation was measured by cell counting, and cell viability was examined by MTT assay. Cell cycle phase distribution and the cytosolic calcium level were detected by flow cytometry. Mitochondrial membrane potential was measured by the JC-1 probe staining and fluorescent microscopy. The expression of an oncogene (c-Myc) and a tumor suppressor [p21 (WAF1/Cip1)] proteins was analyzed by using Western blotting. Erythromycin could inhibit the proliferation of SH-SY5Y cells in a concentration- and time-dependent manner. The cell cycle was arrested at S phase. Mitochondrial membrane potential collapsed and the cytosolic calcium was overloaded in SH-SY5Y cells when treated with erythromycin. The expression of c-Myc protein was down-regulated, while that of p21 (WAF1/Cip1) protein was up-regulated. It was concluded that erythromycin could restrain the proliferation of SH-SY5Y cells. The antitumor mechanism of erythromycin might involve regulating the expression of c-Myc and p21 (WAF1/Cip1) proteins.

Key words

erythromycin c-Myc p21 (WAF1/Cip1) neuroblastoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother, 1991, 27(Suppl A):1–9PubMedGoogle Scholar
  2. 2.
    Reich C. Erythromycin as an aid in the management of aleukemic myeloblastic leukemias. N Y State J Med, 1954,54(15):2208–2209PubMedGoogle Scholar
  3. 3.
    Hofsli E, Nissen-Meyer J. Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer, 1989,44(1):149–154CrossRefPubMedGoogle Scholar
  4. 4.
    Hamada K, Kita E, Sawaki M, et al. Antitumor effect of erythromycin in mice. Chemotherapy, 1995,41(1):59–69CrossRefPubMedGoogle Scholar
  5. 5.
    Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther, 2002,302(1):320–327CrossRefPubMedGoogle Scholar
  6. 6.
    Park J R, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am, 2010,24(1):65–86CrossRefPubMedGoogle Scholar
  7. 7.
    Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. Nat Rev Cancer, 2002,2(5):331–341CrossRefPubMedGoogle Scholar
  8. 8.
    Gorlov IP, Byun J, Gorlova OY, et al. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics, 2009,2:48CrossRefPubMedGoogle Scholar
  9. 9.
    Gearhart J, Pashos EE, Prasad MK. Pluripotency redux—Advances in stem-cell research. N Engl J Med, 2007,357(15):1469–1472CrossRefPubMedGoogle Scholar
  10. 10.
    Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene, 2010,29(9):1249–1259CrossRefPubMedGoogle Scholar
  11. 11.
    Poluha W, Poluha DK, Chang B, et al. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol, 1996,16(4):1335–1341PubMedGoogle Scholar
  12. 12.
    Mckenzie PP, Danks MK, Kriwacki RW, et al. P21Waf1/Cip1 dysfunction in neuroblastoma: a novel mechanism of attenuating G0–G1 cell cycle arrest. Cancer Res, 2003,63(13):3840–3844PubMedGoogle Scholar
  13. 13.
    Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 2002,419(6908): 729–734CrossRefPubMedGoogle Scholar
  14. 14.
    June CH, Moore JS. Measurement of intracellular ions by flow cytometry. Curr Protoc Immunol, 2004, Chapter 5:Unit 5.5Google Scholar
  15. 15.
    Hu Y, Xia XY, Pan LJ, et al. Evaluation of sperm mitochondrial membrane potential in varicocele patients using JC-1 fluorescent staining. Zhonghua Nan Ke Xue (Chinese) 2009,15(9):792–795.Google Scholar
  16. 16.
    Lovmar M, Nilsson K, Vimberg V, et al. The molecular mechanism of peptide-mediated erythromycin resistance. J Biol Chem, 2006,281(10):6742–6750CrossRefPubMedGoogle Scholar
  17. 17.
    Chen SZ, Jiang M, Zhen YS. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother Pharmacol, 2005,56(2):212–220CrossRefPubMedGoogle Scholar
  18. 18.
    Baumann S, Fas SC, Giaisi M, et al. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood, 2008,111(4): 2354–2363CrossRefPubMedGoogle Scholar
  19. 19.
    Dick JE. Stem cell concepts renew cancer research. Blood, 2008,112(13):4793–4807CrossRefPubMedGoogle Scholar
  20. 20.
    Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol, 1999,19(1): 1–11PubMedGoogle Scholar
  21. 21.
    Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer, 2002, 2(10):764–776CrossRefPubMedGoogle Scholar
  22. 22.
    Li F, Wang Y, Zeller KI, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol, 2005,25(14):6225–6234CrossRefPubMedGoogle Scholar
  23. 23.
    Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458(7239):762–765CrossRefPubMedGoogle Scholar
  24. 24.
    Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res, 2009,15(21):6479–6483CrossRefPubMedGoogle Scholar
  25. 25.
    Dominguez-Sola D, Ying CY, Grandori C, et al. Non-transcriptional control of DNA replication by c-Myc. Nature, 2007,448(7152):445–451CrossRefPubMedGoogle Scholar
  26. 26.
    Dai MS, Jin Y, Gallegos JR, et al. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia, 2006,8(8):630–644CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Jia Yongsheng (贾勇圣)
    • 1
  • Ma Xiaoyun (马晓芸)
    • 1
  • Wei Xiaoli (魏晓莉)
    • 1
  • Li Xin (李 昕)
    • 1
  • Yan Haitao (闫海涛)
    • 1
  • Liu Xiaoyan (刘晓燕)
    • 1
  • Zheng Jianquan (郑建全)
    • 1
  1. 1.Beijing Institute of Pharmacology and ToxicologyBeijingChina

Personalised recommendations